Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor

Cancer Gene Therapy

Volumn 12, Issue 3, 2005, Pages 268-275

  Fu, Panfeng ^a   Chen, Junxia ^a   Tian, Yuxiang ^a   Watkins, Tonya ^b   Cui, Xiuyun ^a   Zhao, Baochang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Hematopoietic cell; Ribonuclease inhibitor

Indexed keywords

ACID PROTEIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; COMPLEMENTARY DNA; PANCREATIC RIBONUCLEASE; RETROVIRUS VECTOR; RIBONUCLEASE; RIBONUCLEASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; GROWTH RATE; HEMATOPOIETIC CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CLONING, MOLECULAR; DNA PRIMERS; DNA, COMPLEMENTARY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; PLACENTAL HORMONES; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASE, PANCREATIC; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 14644392203     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700742     Document Type: Article

References (24)

1. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer matastasis. J Natl Cancer Inst. 1995;87:1588-1592.
2. Bouck N, Stellmach V, Hsu S. How tumors become angiogenic. Cancer Res. 1996;69:135-174.
3. Joe Y-A, Hong Y-K, Chung D-S, Yang J-K, Lee Y-S. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer. 1999;82:694-699.
4. Drixler TA, Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000;60:1761-1765.
5. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat. 1995;36:109-118.
6. Fett JW, Strydom DJ, Vallee BL. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985;24:5480-5486.
7. Bikfalvi A, Klein S, Pintucci G, et al. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor possible intracellular signaling by the high molecular weight forms. J Cell Biol. 1995;129:233-243.
8. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis,and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA. 1998;95:10820-10825.
9. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-165.
10. Kurachi K, Davie EW, Vallee BL. Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 1985;24:5494-5499.
11. Drixler TA, Rinkes IH, Ritchie ED, et al. Continuous administration of angistatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000;60:1761-1765.
12. Folkman J. Antiangiogenetic gene therapy. Proc Natl Acad Sci USA. 1998;95:9064-9066.
13. Rybak SM, Sanovich E, Hollingshead MG, et al. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res. 2003;63:2812-2819.
14. Drevs J, Laus C, Mendinger M, Schmidt-Gersbach C, Unger C. Antiangiogenesis: Current clinical data and future perspectives. Onkologie. 2002;25:520-527.
15. Xiuping Y, Yuxiang T, Xiuyun C. Cloning and sequencing of ribonuclease inhibitor. J Pract Oncol. 2000;15:230-232.
16. Frederick MA. Short Protocols in Molecular Biology. 3rd edn. Science Publication Press: Beijing, China; 1998:319-320 (in Chinese).
17. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
18. Dunbar CE. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med. 1996;47:11-20.
19. Brenner MK. Gene transfer to hematopoietic cells. N Engl J Med. 1996;335:337-339.
20. Kerr WG, Mule JJ. Gene therapy: current status and future propects. J Leukoc Biol. 1994;56:210-214.
21. Hanford HA, Wong CA, Kassan H, et al. Angiostatin 4.5-mediated apoptosis of vascular endothelial cells. Cancer Res. 2003;63:4275-4280.
22. O'Reilly MS, Boehm T, Shing Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1999;88:277-285.
23. Polakowski IJ, Lewis MK, Muthukkaruppan VR, et al. A ribonuclease inhibitor expresses antiangiogenic properties and leads to reduced tumor growth in mice. Am J Pathol. 1993;143:507-517.
24. Rafael B-E, Gema M, Fernando R, et al. Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor RNasin. Cancer Gene Ther. 2001;8:278-284.